{"id":62864,"date":"2026-03-30T13:03:14","date_gmt":"2026-03-30T11:03:14","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-present-data-for-its-stat6-inhibitor-program-at-immunology2026tm-the-annual-meeting-of-the-american-association-of-immunologists-aai\/"},"modified":"2026-03-30T13:03:14","modified_gmt":"2026-03-30T11:03:14","slug":"enanta-pharmaceuticals-to-present-data-for-its-stat6-inhibitor-program-at-immunology2026tm-the-annual-meeting-of-the-american-association-of-immunologists-aai","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-present-data-for-its-stat6-inhibitor-program-at-immunology2026tm-the-annual-meeting-of-the-american-association-of-immunologists-aai\/","title":{"rendered":"Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)"},"content":{"rendered":"
\n

WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc.<\/a> (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that preclinical data from the Company\u2019s STAT6 inhibitor program will be presented in four posters at IMMUNOLOGY2026\u2122, the annual meeting of the American Association of Immunologists (AAI), being held April 15-19, 2026 in Boston, MA.<\/p>\n

<\/a>
<\/a><\/p>\n

\nDetails of the presentations are as follows:<\/p>\n

\nPoster Number: <\/b>573
\n
Abstract Number: <\/b>2257506
\n
Title: <\/b>Oral STAT6 Inhibitor EPS-3903 Demonstrates Good Preclinical In Vivo Tolerability without Reactive Metabolites or Metabolic\/Safety Liabilities
\n
Date: <\/b>Thursday, April 16, 2026
\n
Time: <\/b>11:30 AM \u2013 12:30 PM ET
\n
Session Type: <\/b>Therapeutic Approaches to Autoimmunity (THER)
\n
Session Title:<\/b> Therapeutics for Autoimmune Diseases I
\n
Location: <\/b>Exhibit Hall
\n
Presenter: <\/b>Jonathan Kibel and Meng Huang, Ph.D.<\/p>\n

\nPoster Number: <\/b>193
\n
Abstract Number: <\/b>2253997
\n
Title: <\/b>EPS-3903 Is a Potent and Selective Oral STAT6 Inhibitor that Blocks Th2 Inflammation in an Ovalbumin Asthma Mouse Model
\n
Date: <\/b>Friday, April 17, 2026
\n
Time: <\/b>11:30 AM \u2013 12:30 PM ET
\n
Session Type: <\/b>Immediate Hypersensitivity, Asthma, and Allergic Responses (HYP)
\n
Session Title: <\/b>Airway Hypersensitivity and Asthma
\n
Location: <\/b>Exhibit Hall
\n
Presenter: <\/b>Yaohui Nie, Ph.D.<\/p>\n

\nPoster Number: <\/b>194
\n
Abstract Number: <\/b>2257118
\n
Title: <\/b>Discovery and Characterization of a Potent and Selective Oral Inhibitor of STAT6 for the Treatment of Allergic Diseases
\n
Date: <\/b>Friday, April 17, 2026
\n
Time: <\/b>2:30 \u2013 3:30 PM ET
\n
Session Type: <\/b>Immediate Hypersensitivity, Asthma, and Allergic Responses (HYP)
\n
Session Title: <\/b>Airway Hypersensitivity and Asthma
\n
Location: <\/b>Exhibit Hall
\n
Presenter: <\/b>Joyce Sweeney Gibbons, Ph.D.<\/p>\n

\nPoster Number: <\/b>723
\n
Abstract Number: <\/b>2257175
\n
Title: <\/b>Potent STAT6 Inhibitor EPS-3903 Demonstrates Excellent Preclinical Pharmacokinetics Enabling Sustained STAT6 Inhibition following Once-Daily Oral Dosing in Humans
\n
Date <\/b>Saturday, April 18, 2026
\n
Time: <\/b>11:30 AM \u2013 12:30 PM ET
\n
Session Type: <\/b>Therapeutic Approaches to Autoimmunity (THER)
\n
Session Title: <\/b>Therapeutics for Autoimmune Diseases I
\n
Location: <\/b>Exhibit Hall
\n
Presenter: <\/b>Daniel Leonard and Tianzhu Zang, Ph.D.<\/p>\n

\nFurther information about IMMUNOLOGY2026TM<\/sup> can be found here<\/a>. Posters will be available on the Company\u2019s website here<\/a> following each presentation.<\/p>\n

\nAbout Enanta Pharmaceuticals, Inc.
\n
<\/b>Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for viral infections and immunological diseases. Enanta\u2019s clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, with KIT, STAT6 and MRGPRX2 inhibition.<\/p>\n

\nGlecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET\u00ae (U.S.) and MAVIRET\u00ae (ex-U.S.) (glecaprevir\/pibrentasvir). A portion of Enanta\u2019s royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta\u2019s operations. Please visit www.enanta.com<\/a> for more information.<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia and Investors Contact:<\/b>
Jennifer Viera
\n
617-744-3848
\n
jviera@enanta.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that preclinical data from the Company\u2019s STAT6 inhibitor program will be presented in four posters at IMMUNOLOGY2026\u2122, the annual meeting of the American Association of Immunologists (AAI), being held April 15-19, … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62864","6":"format-standard","7":"category-industry"},"yoast_head":"\nEnanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI) - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-present-data-for-its-stat6-inhibitor-program-at-immunology2026tm-the-annual-meeting-of-the-american-association-of-immunologists-aai\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI) - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that preclinical data from the Company\u2019s STAT6 inhibitor program will be presented in four posters at IMMUNOLOGY2026\u2122, the annual meeting of the American Association of Immunologists (AAI), being held April 15-19, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-present-data-for-its-stat6-inhibitor-program-at-immunology2026tm-the-annual-meeting-of-the-american-association-of-immunologists-aai\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-30T11:03:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260316632112\/en\/1475183\/22\/Enanta_RGB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-present-data-for-its-stat6-inhibitor-program-at-immunology2026tm-the-annual-meeting-of-the-american-association-of-immunologists-aai\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-present-data-for-its-stat6-inhibitor-program-at-immunology2026tm-the-annual-meeting-of-the-american-association-of-immunologists-aai\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)\",\"datePublished\":\"2026-03-30T11:03:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-present-data-for-its-stat6-inhibitor-program-at-immunology2026tm-the-annual-meeting-of-the-american-association-of-immunologists-aai\\\/\"},\"wordCount\":489,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-present-data-for-its-stat6-inhibitor-program-at-immunology2026tm-the-annual-meeting-of-the-american-association-of-immunologists-aai\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260316632112\\\/en\\\/1475183\\\/22\\\/Enanta_RGB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-present-data-for-its-stat6-inhibitor-program-at-immunology2026tm-the-annual-meeting-of-the-american-association-of-immunologists-aai\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-present-data-for-its-stat6-inhibitor-program-at-immunology2026tm-the-annual-meeting-of-the-american-association-of-immunologists-aai\\\/\",\"name\":\"Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI) - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-present-data-for-its-stat6-inhibitor-program-at-immunology2026tm-the-annual-meeting-of-the-american-association-of-immunologists-aai\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-present-data-for-its-stat6-inhibitor-program-at-immunology2026tm-the-annual-meeting-of-the-american-association-of-immunologists-aai\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260316632112\\\/en\\\/1475183\\\/22\\\/Enanta_RGB.jpg\",\"datePublished\":\"2026-03-30T11:03:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-present-data-for-its-stat6-inhibitor-program-at-immunology2026tm-the-annual-meeting-of-the-american-association-of-immunologists-aai\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-present-data-for-its-stat6-inhibitor-program-at-immunology2026tm-the-annual-meeting-of-the-american-association-of-immunologists-aai\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-present-data-for-its-stat6-inhibitor-program-at-immunology2026tm-the-annual-meeting-of-the-american-association-of-immunologists-aai\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260316632112\\\/en\\\/1475183\\\/22\\\/Enanta_RGB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260316632112\\\/en\\\/1475183\\\/22\\\/Enanta_RGB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/enanta-pharmaceuticals-to-present-data-for-its-stat6-inhibitor-program-at-immunology2026tm-the-annual-meeting-of-the-american-association-of-immunologists-aai\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI) - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-present-data-for-its-stat6-inhibitor-program-at-immunology2026tm-the-annual-meeting-of-the-american-association-of-immunologists-aai\/","og_locale":"en_US","og_type":"article","og_title":"Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI) - Pharma Trend","og_description":"WATERTOWN, Mass.–(BUSINESS WIRE)–Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases today announced that preclinical data from the Company\u2019s STAT6 inhibitor program will be presented in four posters at IMMUNOLOGY2026\u2122, the annual meeting of the American Association of Immunologists (AAI), being held April 15-19, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-present-data-for-its-stat6-inhibitor-program-at-immunology2026tm-the-annual-meeting-of-the-american-association-of-immunologists-aai\/","og_site_name":"Pharma Trend","article_published_time":"2026-03-30T11:03:14+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260316632112\/en\/1475183\/22\/Enanta_RGB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-present-data-for-its-stat6-inhibitor-program-at-immunology2026tm-the-annual-meeting-of-the-american-association-of-immunologists-aai\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-present-data-for-its-stat6-inhibitor-program-at-immunology2026tm-the-annual-meeting-of-the-american-association-of-immunologists-aai\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)","datePublished":"2026-03-30T11:03:14+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-present-data-for-its-stat6-inhibitor-program-at-immunology2026tm-the-annual-meeting-of-the-american-association-of-immunologists-aai\/"},"wordCount":489,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-present-data-for-its-stat6-inhibitor-program-at-immunology2026tm-the-annual-meeting-of-the-american-association-of-immunologists-aai\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260316632112\/en\/1475183\/22\/Enanta_RGB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-present-data-for-its-stat6-inhibitor-program-at-immunology2026tm-the-annual-meeting-of-the-american-association-of-immunologists-aai\/","url":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-present-data-for-its-stat6-inhibitor-program-at-immunology2026tm-the-annual-meeting-of-the-american-association-of-immunologists-aai\/","name":"Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI) - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-present-data-for-its-stat6-inhibitor-program-at-immunology2026tm-the-annual-meeting-of-the-american-association-of-immunologists-aai\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-present-data-for-its-stat6-inhibitor-program-at-immunology2026tm-the-annual-meeting-of-the-american-association-of-immunologists-aai\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260316632112\/en\/1475183\/22\/Enanta_RGB.jpg","datePublished":"2026-03-30T11:03:14+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-present-data-for-its-stat6-inhibitor-program-at-immunology2026tm-the-annual-meeting-of-the-american-association-of-immunologists-aai\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-present-data-for-its-stat6-inhibitor-program-at-immunology2026tm-the-annual-meeting-of-the-american-association-of-immunologists-aai\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-present-data-for-its-stat6-inhibitor-program-at-immunology2026tm-the-annual-meeting-of-the-american-association-of-immunologists-aai\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260316632112\/en\/1475183\/22\/Enanta_RGB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260316632112\/en\/1475183\/22\/Enanta_RGB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/enanta-pharmaceuticals-to-present-data-for-its-stat6-inhibitor-program-at-immunology2026tm-the-annual-meeting-of-the-american-association-of-immunologists-aai\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62864","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62864"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62864\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62864"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62864"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62864"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}